WO2000055363A2 - Analysis of differential gene expression - Google Patents
Analysis of differential gene expression Download PDFInfo
- Publication number
- WO2000055363A2 WO2000055363A2 PCT/GB2000/000807 GB0000807W WO0055363A2 WO 2000055363 A2 WO2000055363 A2 WO 2000055363A2 GB 0000807 W GB0000807 W GB 0000807W WO 0055363 A2 WO0055363 A2 WO 0055363A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- beads
- reagent
- target
- nucleic acids
- bead
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/005—Beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00664—Three-dimensional arrays
Definitions
- This invention relates to methods for detecting the differential expression or presence of two analytes. and more specifically to procedures which provide for rapid and efficient analysis of gene expression in biological systems.
- Such approaches have largely been displaced by more powerful, reproducible and informative methods based on the use of arrays of nucleic acids in which large numbers of specific sequences are laid down in an ordered pattern on a solid surface and form the target for hybridisation and capture of labelled mRNA or cDNA from the cells under study.
- arrays have been constructed on a variety of supports, ranging from nylon membranes to glass and silicon wafers. Whatever the support, the essential method of use is the same: firstly know n sequences, complementary to cellular mRNAs, either in the form of synthetic oligonucleotides or as PCR products, arc laid down on the solid support in spots at defined locations.
- sequences are then exposed to sequences (probes) extracted from the cells or tissue under study, where the probes are tagged with some form of label which can be detected in subsequent analysis.
- probes In early techniques, radioactive labels were used to probe targets on nylon membranes using techniques developed from Southern and Northern blotting methods. However these methods required the hybridisation process to be performed twice, once for the control sample and once for the test sample. They were subsequently overtaken by more elegant procedures based on the use of different coloured fluorophors to label control and test probes and using either PCR products coupled to glass (Schena M. et al, (1996), Proc. Natl. Acad.
- the mRNA sequences extracted from control and test cells or tissues are either labelled directly or are first converted or amplified to yield equivalent cDNA sequences which are subsequently labelled.
- the fluorescent labels attached to the probes are detected, either by scanning or by imaging, and quantified to yield data on the amounts of different mRNAs present in the test and control samples. Since sequences from test and control cells are labelled with different fluorophors, both samples can be applied and hybridised simultaneously and the resulting pattern and intensity of hybridised probes determined using detection instrumentation tuned to distinguish between the emission wavelengths of the fluorophors used.
- the hybridisation process is also subject to a number of problems arising from the geometry of the system and the temperature required for the hybridisation process.
- This invention provides an alternative to micro-array systems for analysis of gene expression. Means are provided for performing analyses using a particle based technique so as to replace ordered 2D arrays with randomly oriented 3D arrays which can be quickly and easily modified to include new target sequences.
- the technique provides favourable geometry and kinetics for promoting efficient hybridisation, that can be performed in a standard reaction tube, and that allows measurement of hybridised probe to several thousand target sequences to be accomplished in a few seconds.
- the invention provides a method of detecting and analysing differences between nucleic acids from two sources, which method comprises: a. providing nucleic acids from two sources as labelled probes; b.
- each reagent is a population of beads carrying a polynucleotide target, the target of one reagent being different from the target of another reagent, the beads of one reagent being distinguishable from the beads of another reagent; c. incubating the mixture under conditions to promote specific hybridisation between probes and targets; and, d. analysing beads in the mixture by flow cytometry.
- a polynucleotide target is partly or wholly single-stranded and is capable of specific hybridisation. Oligonucleotides of at least 8 residues are preferred.
- cDNA sequences derived, e.g. by RT-PCR amplification, from cellular mRNA.
- the pooled reagents may comprise one bead, or preferably a plurality of beads, of each reagent.
- features of the invention include: a) gene expression assays are performed on carrier beads; b) individually identifiable beads or populations of beads each carrying a different target sequence are prepared; c) selected beads, or populations of beads, are pooled together in suspension to provide a randomly oriented 3D array of particles carrying all sequences of interest for an individual investigation; d) mRNAs or cDNAs prepared from control and test cells or tissues are labelled with fluorescent tags to identify their source; e) labelled probe species are mixed with the pooled suspension of target carrying beads under conditions which promote specific hybridisation between probes and targets; f) the bead mixture is analysed by flow cytometry to simultaneously determine the identity of each bead analysed (and hence the identity of the target sequence carried by the bead) and to quantify the amounts of both control and test probes bound to each bead; and g) data is analysed to yield information on the relative and absolute abundance of each mRNA in the control and test samples.
- the beads of one reagent can be distinguished from the beads of another reagent by a number of different means. Suitable distinguishing means include differences in size, colour or fluorescence or the nature or concentration of markers attached to the beads. Beads of one reagent can be distinguished from beads of other reagents using one or more of such means.
- Figure 1 Schematic illustration of 2D ordered array and 3D random array.
- Figure 2 Flowchart illustrating the principle of the bead based flow cytometry gene expression process.
- Figure 3 Schematic representation of the bead based flow cytometry gene expression process.
- FIG. 4 Schematic representation of method for analysis of differential expression of TNF and GAPDH genes in LPS stimulated THP-1 cells.
- each target spot immobilised on a planar surface are defined by x,y coordinates and hence target sequences are identified by the same co-ordinates.
- a 3D array formed from particles dispersed in a space defined by dimensions x,y,z if each particle is individually identifiable by some inherent characteristic, it is not necessary to use x,y,z locations to specify the identity of each bead and the particles can be randomly distributed throughout the volume as in a suspension of beads in liquid. It follows that if each bead is individually identifiable, then any target sequence previously coupled to that bead is also identifiable. Therefore if a number of differing beads, or discrete populations of beads, are individually prepared where each bead carries a different target sequence and then selectively pooled, the pooled beads can form a 3D array which can be used for gene expression analysis.
- Beads suitable for use in the method of the invention are those which can be readily identified during analysis by flow cytometry; such beads have been previously developed and used for diagnostic assays to measure a wide range of analytes in blood and other biological fluids by immunoassay.
- a desire to have a higher throughput in these applications has led to the development of multiplex methods which allow more than one analyte to be measured simultaneously by means of flow cytometry analysis. Multiplexing is achieved by carrying out solid phase linked assays using plastic or latex beads as assay substrates.
- each bead type carries reagents for one assay
- standard flow cytometer instrumentation may be used both to identify the bead type and to measure the assay signal associated with each bead. Discrimination between bead populations can be achieved by size (Frengen I. et al (1995), Journal of Immunological Methods, Volume 178, pi 41 ), by colour or fluorescence (Fulwyier M.J. UK Patent 1 ,561 ,042) or by electronic means (Mandecki W. US Patent 5,641,634).
- Selected target cDNA sequences are prepared by standard PCR methods incorporating a means to allow coupling of target sequences to beads.
- One suitable method would utilise a 5'-biotin on one of the PCR primers, yielding a 5'- biotinylated DNA suitable for coupling to streptavidin-coated beads.
- alternative chemical coupling strategies are available. Such alternative strategies may include, for example, synthesising oligonucleotides having a chemical group such as an amino group at the 5' end thus rendering them suitable for crosslinking to beads which have been modified to have, for example, carboxyl groups on their surface. It will also be appreciated that oligonucleotides synthesised with a terminal biotin or other coupling group could readily be used in place of PCR generated DNA sequences.
- each target sequence is separately coupled to a corresponding discrete population of beads (Bead 1 to Bead n respectively). Aliquots are then removed from each population and pooled to form a mixed suspension of beads constituting a randomly orientated 3D array of target sequences.
- the 3D array is then hybridised with fluorescently labelled probes (RNA or cDNA) prepared from the control and target cells or tissues which have been labelled with two different fluorophors (Fluor A and Fluor B respectively).
- the mixed population of beads is analysed by flow cytometry; as each bead is analysed info ⁇ nation from the flow cytometer detectors is used to identify the bead and to measure the amounts of Fluor A (control mRNA) and Fluor B (sample mRNA) bound to the complementary target sequence carried by the bead. These measurements are then used to determine the relative expression of each mRNA in the samples.
- Control (1) and test (2) probes are prepared and labelled using standard methods and aliquots mixed in a tube (3) containing a mixture of beads (4) carrying the desired target sequences and the tube sealed. Hybridisation of probe and target sequences are promoted by incubating the mixture under conditions of heat, pH and salt concentration which are known to allow the formation of specific nucleic acid hybrids. Following hybridisation, the bead mixture is analysed by flow cytometry using multiple channel fluorescence detection. In the embodiment illustrated, two fluorescence channels are used to identify beads and two further channels are used to measure control and test probe fluorescence.
- Bead identity is determined by measuring the amounts of two different fluorophors (bead Fluor 1 and bead Fluor 2) incorporated within the bead during manufacture. Plotting the intensities of the two fluorophors on x,y axes (8 & 9) separates the different bead populations used.
- the number of possible target sequences that can be measured in a single assay will necessarily be limited by the number of bead populations which it is possible to discriminate in a mixture. With current flow cytometry instrumentation this does not pose a limitation on the utility of the procedure.
- Typical modern flow cytometry instruments are capable of simultaneously measuring fluoresce.nce at four wavelengths together with other parameters, for example light scattering which is a measure of the size of particles under analysis.
- the dynamic range of fluorescence detection is high and fluorescence may be accurately measured over several orders of magnitude.
- Plotting the intensity of probe fluorophors on the z axis of two different plots (10 & 1 1 ) shows the amounts of the control (10) and test (1 1 ) probes bound to each bead population. This allows the production of a table of the amounts bound to each target sequence in the analysis (14).
- one mRNA species (12) is expressed at a lower level in the test sample than in the control (13). Other differences in expression can be readily identified as differences in the heights of equivalent peaks in the two plots.
- DNA or oligonucleotide target sequences are typically applied to a solid surface as discrete areas of dimensions in the range 10-100 ⁇ m, with dimensions of 50-100 ⁇ m being typical of DNA spots applied as liquid droplets, and smaller areas being used in techniques utilising photo-lithographic oligonucleotide synthesis.
- Beads used for flow cytometry typically have diameters in the range from 1 -10 ⁇ m and therefore individually do not have sufficient surface area to substitute for a typical micro-array.
- Beads used for flow cytometry typically have diameters in the range from 1 -10 ⁇ m and therefore individually do not have sufficient surface area to substitute for a typical micro-array.
- Beads to carry each target sequence it is possible to achieve equivalence in target presentation as shown in the following example:
- spot area ⁇ r
- the total volume required for the assay is 1 ⁇ l. If desired, larger volumes may be used for convenience in hybridisation or analysis; for example using beads at a concentration of 1 % v/v would give a 10 ⁇ l total volume.
- the method of the invention would allow larger numbers of beads to be used with a consequent increase in capacity for binding a greater mass of target sequence spread over the total bead population. This would allow the user if desired to increase the amount of probe bound to the bead populations to increase the sensitivity of the process for detecting rare species. Alternatively, it enables an increase in the number of samples which may be analysed simultaneously, for example, to measure expression of a panel of genes simultaneously in a control and more than one test sample, where as described previously each control or test sample is labelled with a different fluorophor. Such increases in assay complexity are not achievable with conventional arrays on solid surfaces without reducing sensitivity due to the finite capacity of array spots for binding complementary sequences.
- the method of the present invention provides a number of significant advantages over previously described procedures for gene expression analysis which are based on 2D arrays: a) the basic components for the bead based assay are readily prepared by coupling solutions of cDNA or oligonucleotides to commercially available beads using standard coupling methods, b) no specialised equipment is required for preparation or analysis, in contrast to the dedicated array production and scanning equipment required for micro- arrays, c) the design of investigations can be easily modified with target sequences being added or deleted at will without the requirement to scrap existing materials, d) hybridisation is performed in suspension in standard reaction vessels, thereby avoiding problems with evaporation associated with thin films of liquid covering micro-arrays and promoting hybridisation through efficient mixing of probe and target sequences, and e) analysis speed is significantly improved: flow cytometers typically analyse beads at rates of 1,000-10,000 beads/second allowing processing of a 100 sequence gene expression analysis in a few seconds.
- FIG. 4 shows a scheme of a method for the analysis of differential Tumour Necrosis Factor (TNF) expression in THP-1 cells either treated in the presence (test) or absence (control) of bacterial lipopolysaccharide (LPS) (Su S. etal BioTechniques 1997, 22: 1 107-1 1 13).
- LPS bacterial lipopolysaccharide
- GPDH glyceraldehyde-3-phosphate dehydrogenase
- RNA isolation RNA isolation will be recognised by someone skilled in the art and include the use of commercially available reagents or kits (e.g. RNeasy, Qiagen).
- RNA molecules are converted to cDNA by means of the enzyme, reverse transcriptase, using the standard method set out in Molecular Cloning, A Laboratory Manual, Cold Spring Harbour Laboratory Press 1989, pp 8.1 1 -8.13.
- cDNA molecules obtained from each sample are then used in separate multiplex PCR reactions using standard conditions (Molecular Cloning, A Laboratory Manual, Cold Spring Harbour Laboratory Press 1989 pp 14.5-14.20) and primer pairs which amplify GAPDH and TNF (Su S. etal BioTechniques 1997,
- One primer of each primer pair is modified at the 5 ' end with a biotin molecule to aid in strand separation in subsequent steps in the process. This is readily achieved using standard techniques during oligonucleotide synthesis with modified phosphoramidites, for example : 5'-Biotin Phosphoramidite (Glen Research). Fluorescently labelled nucleotides are incorporated into the PCR reactions in order to label the amplified PCR products such that their origin from the test or control RNA populations may be established.
- the PCR reaction mix containing cDNAs prepared from the control cells includes Cy3TM-dCTP and the reaction mix containing cDNAs prepared from test cells includes Cy5TM-dCTP (Cy3TM-dCTP and Cy5TM-dCTP are obtained from Amersham Pharmacia Biotech).
- Cy3TM-dCTP and Cy5TM-dCTP are obtained from Amersham Pharmacia Biotech.
- Double stranded cDNA products of the PCR reactions are converted to single stranded cDNA molecules prior to further analysis by binding the PCR products via the biotin at the 5' end of each PCR product to streptavidin-coated magnetic beads (MagneSphere, Promega).
- the double stranded PCR products are denatured by addition of 0.2 volume of 2M NaOH, incubating for 10 minutes at room temperature in order to release the non-biotinylatcd strands from the beads.
- the beads are separated from the solution by attraction to a magnet and the clarified solution, which contains the single stranded labelled PCR products, is removed and made neutral by addition of 1 volume of 0.4M HC1.
- Other methods for separating double-stranded DNA molecules are known to those skilled in the art.
- populations of beads or particles suitable for performing analysis of differential gene expression are prepared using beads containing fluorescent dyes (SPHEROTM, Spherotech Inc.). Yellow fluorescent streptavidin-coated beads are coated with the 5 ' -biotin primer for GAPDH and blue fluorescent streptavidin-coated beads are coated with the 5 '-biotin primer for TNF (using the same 5' -biotin primers as were used earlier).
- these populations of beads have two distinguishing characteristics i.e. each bead population is distinguishable from all other bead populations by its fluorescence characteristics and each bead population is capable of recognising a single cDNA species (either TNF or GAPDH).
- the separately prepared beads are mixed together, further mixed with the Cy 3 and Cy 5-labelled single stranded cDNA products prepared previously and incubated in a hybridisation buffer (0.1M Tris.HCl pH7.4, 750mM NaCl) at 45° for 2 hours prior to analysis of the bead populations by flow cytometry.
- a hybridisation buffer 0.1M Tris.HCl pH7.4, 750mM NaCl
- cDNA products from the mixed population will bind specifically to their complementary capture sequences carried on beads such that each bead will ultimately be decorated with a mixture of labelled cDNAs of a single species arising from the test and control populations, and where the relative abundance of the labels reflects the relative abundance of single species in the original test and control populations.
- the relative abundance of GAPDH transcripts in the population of molecules derived from control and test samples is compared by detecting the fluorescence of yellow beads at 460nm/ 480nm (excitation/emission); and, within the population of yellow beads, bound Cy3 labelled transcripts are detected at 550nm/570nm (excitation emission) and bound Cy5 labelled transcripts are detected at 650nm/670nm (excitation/emission).
- the relative abundance of TNF transcripts in the molecules derived from test and control samples is determined by detecting the fluorescence of blue beads at 650nm/710nm (excitation/emission); and further detecting bound Cy3 labelled transcripts at 550nm/570nm (excitation/emission) and bound Cy5 labelled transcripts at 650nm/670nm (excitation/emission).
- bead fluorescence is used to assign the identity of the gene associated with each bead
- label fluorescence is used to determine the relative abundance of cD As arising from the test and control samples which are attached to the bead, the latter yielding information on the differential expression of that gene under the conditions used in treatment of the original cell or tissue sample.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU29284/00A AU2928400A (en) | 1999-03-12 | 2000-03-09 | Analysis of differential gene expression |
EP00907817A EP1163367A2 (en) | 1999-03-12 | 2000-03-09 | Analysis of differential gene expression |
JP2000605779A JP2002538836A (en) | 1999-03-12 | 2000-03-09 | Analysis of changes in gene expression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9905807.5A GB9905807D0 (en) | 1999-03-12 | 1999-03-12 | Analysis of differential gene expression |
GB9905807.5 | 1999-03-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000055363A2 true WO2000055363A2 (en) | 2000-09-21 |
WO2000055363A3 WO2000055363A3 (en) | 2000-12-21 |
Family
ID=10849574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/000807 WO2000055363A2 (en) | 1999-03-12 | 2000-03-09 | Analysis of differential gene expression |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1163367A2 (en) |
JP (1) | JP2002538836A (en) |
AU (1) | AU2928400A (en) |
GB (1) | GB9905807D0 (en) |
WO (1) | WO2000055363A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001027328A1 (en) * | 1999-10-08 | 2001-04-19 | University Of Utah Research Foundation | Particle analysis assay for biomolecular quantification |
WO2002064829A2 (en) * | 2001-02-13 | 2002-08-22 | Smartbead Technologies Limited | Biochemical method and apparatus for detecting genetic characteristics |
WO2002065123A2 (en) * | 2001-02-13 | 2002-08-22 | Smartbead Technologies Limited | Biochemical method and apparatus for detecting protein characteristics |
WO2004106931A1 (en) * | 2003-05-26 | 2004-12-09 | Institut Virion\Serion Gmbh | Method and testing system for analyzing and/or detecting biomolecules and/or active substances in liquid samples |
WO2005071412A2 (en) | 2004-01-09 | 2005-08-04 | Applera Corporation | Phosphor particle coded beads |
US6994971B1 (en) | 1999-10-08 | 2006-02-07 | University Of Utah Research Foundation | Particle analysis assay for biomolecular quantification |
EP2196544A1 (en) | 2001-11-21 | 2010-06-16 | Applied Biosystems, LLC | Kit for ligation detection assays using codeable labels |
US8129115B2 (en) | 2006-06-06 | 2012-03-06 | Panasonic Corporation | Method of modifying nucleotide chain |
EP2975123A4 (en) * | 2013-03-12 | 2016-11-30 | Hitachi Ltd | Two-dimensional cell array device and apparatus for gene quantification and sequence analysis |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012014A1 (en) * | 1994-10-13 | 1996-04-25 | Lynx Therapeutics, Inc. | Molecular tagging system |
WO1997014028A2 (en) * | 1995-10-11 | 1997-04-17 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
WO1998026098A1 (en) * | 1996-12-13 | 1998-06-18 | Arcaris, Inc. | Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom |
WO1999019515A1 (en) * | 1997-10-14 | 1999-04-22 | Luminex Corporation | Precision fluorescently dyed particles and methods of making and using same |
WO1999035293A2 (en) * | 1998-01-09 | 1999-07-15 | Lynx Therapeutics, Inc. | Solid phase selection of differentially expressed genes |
WO1999064867A1 (en) * | 1997-12-04 | 1999-12-16 | Amersham Pharmacia Biotech Uk Limited | Multiple assay method |
-
1999
- 1999-03-12 GB GBGB9905807.5A patent/GB9905807D0/en not_active Ceased
-
2000
- 2000-03-09 JP JP2000605779A patent/JP2002538836A/en active Pending
- 2000-03-09 WO PCT/GB2000/000807 patent/WO2000055363A2/en not_active Application Discontinuation
- 2000-03-09 EP EP00907817A patent/EP1163367A2/en not_active Withdrawn
- 2000-03-09 AU AU29284/00A patent/AU2928400A/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012014A1 (en) * | 1994-10-13 | 1996-04-25 | Lynx Therapeutics, Inc. | Molecular tagging system |
WO1997014028A2 (en) * | 1995-10-11 | 1997-04-17 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
WO1998026098A1 (en) * | 1996-12-13 | 1998-06-18 | Arcaris, Inc. | Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom |
WO1999019515A1 (en) * | 1997-10-14 | 1999-04-22 | Luminex Corporation | Precision fluorescently dyed particles and methods of making and using same |
WO1999064867A1 (en) * | 1997-12-04 | 1999-12-16 | Amersham Pharmacia Biotech Uk Limited | Multiple assay method |
WO1999035293A2 (en) * | 1998-01-09 | 1999-07-15 | Lynx Therapeutics, Inc. | Solid phase selection of differentially expressed genes |
Non-Patent Citations (4)
Title |
---|
DATABASE ONLINE [Online] LUMINEX CORP/NEWS RELEASE, October 1998 (1998-10) "LUMINEX AWARDED GRANT TO DEVELOP DNA TECHNOLOGY" XP002145219 * |
LACKNER ET AL.: "MULTIPLEX DNA-UND RNA-ANALYSE AN FLUORESZENTEN MICROBEADS ALS ALTERNATIVE ZUM DNA-ARRAY" MEDIZINISCHE GENETIK, vol. 11, March 1999 (1999-03), pages 16-17, XP000930079 * |
SCHENA M ET AL: "QUANTITATIVE MONITORING OF GENE EXPRESSION PATTERNS WITH A COMPLEMENTARY DNA MICROARRAY" SCIENCE, vol. 270, no. 5235, 20 October 1995 (1995-10-20), pages 467-470, XP000644675 ISSN: 0036-8075 * |
VAN NESS J ET AL: "A VERSATILE SOLID SUPPORT SYSTEM FOR OLIGODEOXYNUCLEOTIDE PROBE -BASED HYBRIDIZATION ASSAYS" NUCLEIC ACIDS RESEARCH, vol. 19, no. 12, 25 June 1991 (1991-06-25), pages 3345-3350, XP000208399 ISSN: 0305-1048 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001027328A1 (en) * | 1999-10-08 | 2001-04-19 | University Of Utah Research Foundation | Particle analysis assay for biomolecular quantification |
US8034555B2 (en) | 1999-10-08 | 2011-10-11 | University Of Utah Research Foundation | Particle analysis assay for biomolecular quantification |
US6994971B1 (en) | 1999-10-08 | 2006-02-07 | University Of Utah Research Foundation | Particle analysis assay for biomolecular quantification |
WO2002064829A3 (en) * | 2001-02-13 | 2002-12-12 | Smartbead Technologies Ltd | Biochemical method and apparatus for detecting genetic characteristics |
WO2002065123A3 (en) * | 2001-02-13 | 2002-12-12 | Smartbead Technologies Ltd | Biochemical method and apparatus for detecting protein characteristics |
WO2002065123A2 (en) * | 2001-02-13 | 2002-08-22 | Smartbead Technologies Limited | Biochemical method and apparatus for detecting protein characteristics |
WO2002064829A2 (en) * | 2001-02-13 | 2002-08-22 | Smartbead Technologies Limited | Biochemical method and apparatus for detecting genetic characteristics |
EP2196544A1 (en) | 2001-11-21 | 2010-06-16 | Applied Biosystems, LLC | Kit for ligation detection assays using codeable labels |
WO2004106931A1 (en) * | 2003-05-26 | 2004-12-09 | Institut Virion\Serion Gmbh | Method and testing system for analyzing and/or detecting biomolecules and/or active substances in liquid samples |
WO2005071412A2 (en) | 2004-01-09 | 2005-08-04 | Applera Corporation | Phosphor particle coded beads |
US8129115B2 (en) | 2006-06-06 | 2012-03-06 | Panasonic Corporation | Method of modifying nucleotide chain |
EP2975123A4 (en) * | 2013-03-12 | 2016-11-30 | Hitachi Ltd | Two-dimensional cell array device and apparatus for gene quantification and sequence analysis |
US10030240B2 (en) | 2013-03-12 | 2018-07-24 | Hitachi, Ltd. | Two-dimensional cell array device and apparatus for gene quantification and sequence analysis |
Also Published As
Publication number | Publication date |
---|---|
JP2002538836A (en) | 2002-11-19 |
WO2000055363A3 (en) | 2000-12-21 |
AU2928400A (en) | 2000-10-04 |
EP1163367A2 (en) | 2001-12-19 |
GB9905807D0 (en) | 1999-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6489159B1 (en) | Polymeric arrays and methods for their use in binding assays | |
EP1307743B1 (en) | Colloid compositions for solid phase biomolecular analytical systems | |
NO329977B1 (en) | Method of showing at least one nucleic acid template and sets of at least one nucleic acid template in a sample | |
US6448387B1 (en) | Polymeric arrays adapted for high expressing polynucleotides | |
EP1356860A2 (en) | Quality control method of DNA microarray | |
CA2424176A1 (en) | Multiplexed cell analysis system | |
EP1163367A2 (en) | Analysis of differential gene expression | |
US20030152931A1 (en) | Nucleic acid detection device and method utilizing the same | |
US20100029492A1 (en) | Nucleic acid chip for obtaining binding profile of single strand nucleic acid and unknown biomolecule, manufacturing method thereof and analysis method of unknown biomolecule using nucleic acid chip | |
US20030073091A1 (en) | Use of generic oligonucleotide microchips to detect protein-nucleic acid interactions | |
US20030044808A1 (en) | Method and system of single labeling and parallel analysis of differential gene | |
US20080254448A1 (en) | Analysis Chip With Reference Range, Kits and Methods of Analysis | |
US20060084101A1 (en) | Two-color chemiluminescent microarray system | |
KR20040035248A (en) | Method for identification and analysis of certain molecules using single strand nucleic acid array and nucleic acid ligands to e. coli therefor | |
KR100670799B1 (en) | Method for identification and analysis of certain molecules using the dual function of single strand nucleic acid | |
JP2005528909A (en) | Method for improving combinatorial oligonucleotide PCR | |
JP3944576B2 (en) | Aptamer acquisition method using microarray | |
US20090156428A1 (en) | Multi-mode microarray apparatus and method for concurrent and sequential biological assays | |
US20230099994A1 (en) | Digital polymerase chain reaction (dpcr) platforms on next generation sequencer patterned flow cell technology | |
JP2004298018A (en) | Method for separating and recovering nucleic acid with array for reaction to convert probe into solid phase | |
US20050239078A1 (en) | Sequence tag microarray and method for detection of multiple proteins through DNA methods | |
US20200354776A1 (en) | Method and device for analysing nucleic acids | |
JP2002296280A (en) | Method of analyzing gene expression frequency using capillary array | |
WO2023059935A1 (en) | Fluorescent barcoding of microparticles | |
WO2023107598A1 (en) | Single-cell culture and sequencing with lipid-modified oligos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000907817 Country of ref document: EP |
|
ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 2000 605779 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000907817 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09914603 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000907817 Country of ref document: EP |